839
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Difficulties and advancements in developing drugs for the treatment of dengue fever

, PhD (Investigator) & , PhD (Executive Director)
Pages 947-949 | Published online: 12 Nov 2013
 

Abstract

Dengue fever is caused by infections with dengue virus, the most prevalent mosquito-borne viral pathogen in humans. There are no drugs available to treat dengue virus infection. Here, we discuss the strategies and challenges to develop dengue drugs. Treating the disease pathology is hindered by a lack of understanding of the disease progression and the causes of disease symptoms such as vascular leakage. Most drug-discovery efforts have concentrated on viral targets, which have their own particular challenges. Despite various challenges, great progresses have been made towards the development of dengue therapy. Ultimately, the only way to know whether a direct-acting antiviral will be a viable approach for treating dengue patients is to test safe compounds with demonstrated antiviral activity in human trials.

Declaration of interest

The authors work for a pharmaceutical company and have received no payment in preparation of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.